Acute Hepatitis C in Patients Receiving Hemodialysis

Griveas, Ioannis; Visvardis, G.; Morice, Yoann; Perelson, Alan S.; Pawlotsky, Jean‐Michel; Papadopoulou, Dorothea

doi:10.1080/08860220701460160

Cited by 12 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six studies were excluded because they did not fulfill the inclusion criteria [Potthoff et al, 2005;Carbognin et al, 2006;Caro et al, 2007;Engel et al, 2007;Griveas et al, 2007;Lederer et al, 2008] or contained duplicate reports of the same patients [Kokoglu et al, 2006]. Three studies concerned pegylated IFN for acute hepatitis C [Engel et al, 2007;Griveas et al, 2007;Lederer et al, 2008]. The remaining 16 studies [Mukherjee et al, 2003;Annichiarico and Siciliano, 2004;Rivera et al, 2005;Teta et al, 2005;Covic et al, 2006;Russo et al, 2006;Sporea et al, 2006;Amarapurkar et al, 2007;Casanovas-Taltavull et al, 2007;Chan et al, 2007;Espinosa et al, 2007;Akhan et al, 2008;Ayaz et al, 2008;Liu et al, 2008;Sikole et al, 2008;UcMak et al, 2008] representing a total of 254 unique patients, were included in the metaanalysis.…”

Section: Literature Reviewmentioning

confidence: 97%

“…All candidate studies were written in English. Six studies were excluded because they did not fulfill the inclusion criteria [Potthoff et al, 2005;Carbognin et al, 2006;Caro et al, 2007;Engel et al, 2007;Griveas et al, 2007;Lederer et al, 2008] or contained duplicate reports of the same patients [Kokoglu et al, 2006]. Three studies concerned pegylated IFN for acute hepatitis C [Engel et al, 2007;Griveas et al, 2007;Lederer et al, 2008].…”

Section: Literature Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta‐analysis of clinical trials

Fabrizi

Dixit

Messa

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

The efficacy and safety of pegylated interferon monotherapy in patients with chronic renal failure and chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. A systematic review of the literature with a meta-analysis of clinical trials was performed in order to assess efficacy and safety of initial pegylated interferon monotherapy in chronic renal failure patients with chronic hepatitis C. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). The random effects model of Der Simonian and Laird was used, with heterogeneity and sensitivity analyses. Sixteen clinical trials (254 unique patients) were identified, five (31%) being controlled studies; the majority (15/16 = 94%) regarded patients on long-term dialysis. The summary estimate for sustained virological response and drop-out rate was 33% [95% Confidence Intervals (95%CI) 24-43] and 23% (95%CI, 14-33), respectively. The most frequent side-effects requiring interruption of treatment were haematological (18%) and gastrointestinal (14%). In the group of controlled clinical trials, the summary estimate for sustained viral response and drop-out rate was 38% (95% CI, 18-59), and 15% (95% CI, 3-26), respectively. The studies were heterogeneous with regard to sustained virological response and drop-out rate. Pegylated IFN does not provide an added benefit in terms of virological response in comparison with standard IFN monotherapy. Tolerance to pegylated-IFN monotherapy was unsatisfactory. Prospective trials are in progress to assess the optimal antiviral therapy for chronic hepatitis C in dialysis patients.

show abstract

Section: Literature Reviewmentioning

confidence: 97%

Section: Literature Reviewmentioning

confidence: 99%

Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta‐analysis of clinical trials

Fabrizi

Dixit

Messa

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Little is known regarding the treatment of acute hepatitis C in this population, and only a small number of observational studies have been published [61][62][63]. In general, these studies demonstrated that IFN alfa or PEG-IFN alfa therapy is effective; each produced SVR rates of 57-86% and was well tolerated [61,62,64,65], but further studies are required.…”

Section: Treatment Of Acute Hepatitis C Among Hemodialysis Patientsmentioning

confidence: 98%

Acute hepatitis C: Current status and remaining challenges

Santantonio

Gerlach

2008

Journal of Hepatology

135

108

View full text Add to dashboard Cite

The acute phase of hepatitis C virus (HCV) infection represents a key point in the evolution of hepatitis C. In some patients, the infection resolves spontaneously, whereas in others it develops into chronic disease. However, because acute hepatitis C is often asymptomatic, detection and diagnosis are usually difficult. What is more, there are no established treatment guidelines, leaving physicians to make several challenging decisions, such as whether to treat, when to treat and what treatment regimen to use. Pegylated interferon alfa monotherapy is most commonly used to treat patients with acute hepatitis C; the role of ribavirin has yet to be established. In this review, we discuss the epidemiology of acute hepatitis C, its risk factors and routes of transmission and current treatment practices. We also discuss data from published clinical studies and focus on unresolved issues for which additional studies are needed in order to establish standardized treatment guidelines for the management of acute hepatitis C.

show abstract

“…Recent recommendations to monitor ALT in HD population may facilitate detection of cases of acute HCV [122][123][124][125][126][127][128].…”

Section: Therapy Of Acute Hcv In Ckd Population (Dialysis Patients)mentioning

confidence: 99%

Hepatitis C virus and kidney disease

Martin

Fabrizi

2008

Journal of Hepatology

103

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection remains frequent in patients on renal replacement therapy and has an adverse impact on survival in infected patients on chronic hemodialysis as well as renal transplant (RT) recipients. Nosocomial spread of HCV within dialysis units continues to occur. HCV is also implicated in the pathogenesis of renal dysfunction often mediated by cryoglobulins leading to chronic kidney disease as well as impairing renal allograft function. The role of antiviral therapy for hepatitis C in patients with renal failure remains unclear. Monotherapy with conventional interferon (IFN) for chronic hepatitis C is probably more effective in dialysis than in non-uraemic patients but tolerance is lower. Limited data only are available about monotherapy with pegylated interferon and combination therapy (pegylated IFN plus ribavirin) for chronic HCV in the dialysis population. Clinical experience with antiviral therapy for acute HCV in dialysis population is encouraging. Interferon remains contraindicated post-RT because of concerns about precipitating graft dysfunction. Sustained viral responses obtained by antiviral therapy in renal transplant candidates are durable after renal transplantation and may reduce HCV-related complications after RT (post-transplant diabetes mellitus, HCV-related glomerulonephritis, and chronic allograft nephropathy).

show abstract

Acute Hepatitis C in Patients Receiving Hemodialysis

Cited by 12 publications

References 15 publications

Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta‐analysis of clinical trials

Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta‐analysis of clinical trials

Acute hepatitis C: Current status and remaining challenges

Hepatitis C virus and kidney disease

Contact Info

Product

Resources

About